BCL2 and medulloblastoma: CUR was also reported as a beneficial adjuvant with TMZ and etoposide as this triple combination induced apoptosis by downregulatiing p10 and p53 mRNAs with a concomitant rise in Bcl-2-associated X protein/B-cell lymphoma 2 (BAX/Bcl-2) mRNA ratio at IC50 doses, in comparison with the individual or the dual drug combination in GB and medulloblastoma cell lines (40).